Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$68.48M$68.48Mderived+791.7% vs Q4 2024 Net Income-$68.01M-$68.01MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$62,548,000N/M Operating Cash Flowderived-$69,488,000N/M Margins · derivedOperating margin-91.3%+1163.4 pt vs Q4 2024
Net margin-99.3%+1126.8 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 26, 2026 · 57 d after period end